The European Directorate for the Quality of Medicines & HealthCare (EDQM) released the revised CEP (Certificate of Suitability to the European Pharmacopoeia) Guideline on April 24. Following a two-month transition period, the new requirements will come into effect on July 1 and are expected to have a significant impact on the compliance activities of API manufacturers exporting to the European Union.

The revised guideline maintains the four-tier variation classification system, consisting of Annual Notification, Immediate Notification, Minor Variation, and Major Variation. It also clearly defines six situations that require the submission of a new CEP application rather than a variation application:

• Addition of a manufacturing site outside the company group;
• Conversion of a non-sterile manufacturing process to a sterile process;
• Change of raw material source;
• Modification of the crystal form or hydrate form;
• Significant changes to the synthetic route;
• Changes to the impurity profile.

API manufacturers are advised to promptly review their existing CEP dossiers and change control procedures to ensure compliance with the revised guideline and avoid potential disruptions to EU market access resulting from an inappropriate regulatory submission strategy.

The simplified administrative requirements apply to veterinary active pharmaceutical ingredients (APIs), excluding sterile APIs and biological APIs. This revision further strengthens requirements for variation control and traceability. Relevant companies are advised to promptly optimize their internal procedures and quality management systems to ensure ongoing regulatory compliance.

Information Sources

Guideline on requirements for revision/renewal of certificates of suitability to the European Pharmacopoeia monographs (PA/PH/CEP (04) 02, 8R), EDQM, 24 April 2026

Disclaimer

This article is for industry information exchange and reference only. It does not constitute any investment advice, medical advice, or business decision-making basis. The data and views presented herein are derived from publicly available authoritative sources, but we make no express or implied warranties regarding their accuracy, completeness, or timeliness. Any decisions made by readers based on this information are at their own risk.